RxDoctor Payments Data

John Wright, MD

Family Medicine · Port Lavaca, TXNPI 1215086228

Payments from drug & device makers

$1,020in general payments, 2019–2025

Across 56 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$264
  • Lilly USA, LLC$178
  • GSK$98
  • Amgen$86
  • Ironshore Pharmaceuticals Inc.$77
  • Pfizer$45
  • plus $274 from 12 others

What the payments were for

  • Food & beverage$1,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,020 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$72,039
Medicare patients
421
Services billed
3,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$97,532
OzempicSemaglutide71$95,553
JardianceEmpagliflozin136$76,568
EliquisApixaban89$54,782
JanuviaSitagliptin Phosphate73$36,194
RybelsusSemaglutide14$31,035
Synjardy XrEmpagliflozin/Metformin Hcl13$19,232
Soliqua 100-33Insulin Glargine/Lixisenatide18$19,172
TradjentaLinagliptin35$18,877
TrulicityDulaglutide14$17,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,266
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$14,659
MyrbetriqMirabegron39$14,115
LinzessLinaclotide17$12,481
Atorvastatin Calcium722$8,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$264$126,58785 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Spiriva Respimat$33$120,852196 claims
Lilly USA, LLCMounjaro, Trulicity$178$115,25888 claims
PfizerEliquis$45$54,78289 claims
MerckJanuvia$25$36,19473 claims
GSKTrelegy Ellipta, Breo Ellipta$98$22,74440 claims
Astellas Pharma US IncMyrbetriq$14$14,11539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Port Lavaca

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →